Integrative evaluation of primary and metastatic lesion spectrum to guide anti-PD-L1 therapy of non-small cell lung cancer: results from two randomized studies.
Saved in:
| Title: | Integrative evaluation of primary and metastatic lesion spectrum to guide anti-PD-L1 therapy of non-small cell lung cancer: results from two randomized studies. |
|---|---|
| Authors: | Ma SC; Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.; Information Management and Big Data Center, Nanfang Hospital, Southern Medical University, Guangzhou, China., Tang XR; Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China., Long LL; Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China., Bai X; Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China., Zhou JG; Department of Radiation Oncology, University Hospital Erlangen, Erlangen, Germany., Duan ZJ; Information Management and Big Data Center, Nanfang Hospital, Southern Medical University, Guangzhou, China., Wang J; Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China., Fu QJ; Department of Community Health, Tufts University, Medford, USA., Zhu HB; Information Management and Big Data Center, Nanfang Hospital, Southern Medical University, Guangzhou, China., Guo XJ; Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China., Zhang YP; Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.; Information Management and Big Data Center, Nanfang Hospital, Southern Medical University, Guangzhou, China., Guo ZQ; Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China., Wu DH; Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China., Dong ZY; Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China. |
| Source: | Oncoimmunology [Oncoimmunology] 2021 Apr 26; Vol. 10 (1), pp. 1909296. Date of Electronic Publication: 2021 Apr 26. |
| Publication Type: | Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101570526 Publication Model: Electronic Cited Medium: Internet ISSN: 2162-402X (Electronic) Linking ISSN: 21624011 NLM ISO Abbreviation: Oncoimmunology Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Links: – Type: pdflink Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 33996262 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Integrative evaluation of primary and metastatic lesion spectrum to guide anti-PD-L1 therapy of non-small cell lung cancer: results from two randomized studies. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Ma+SC%22">Ma SC</searchLink>; Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.; Information Management and Big Data Center, Nanfang Hospital, Southern Medical University, Guangzhou, China.<br /><searchLink fieldCode="AU" term="%22Tang+XR%22">Tang XR</searchLink>; Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.<br /><searchLink fieldCode="AU" term="%22Long+LL%22">Long LL</searchLink>; Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.<br /><searchLink fieldCode="AU" term="%22Bai+X%22">Bai X</searchLink>; Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.<br /><searchLink fieldCode="AU" term="%22Zhou+JG%22">Zhou JG</searchLink>; Department of Radiation Oncology, University Hospital Erlangen, Erlangen, Germany.<br /><searchLink fieldCode="AU" term="%22Duan+ZJ%22">Duan ZJ</searchLink>; Information Management and Big Data Center, Nanfang Hospital, Southern Medical University, Guangzhou, China.<br /><searchLink fieldCode="AU" term="%22Wang+J%22">Wang J</searchLink>; Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.<br /><searchLink fieldCode="AU" term="%22Fu+QJ%22">Fu QJ</searchLink>; Department of Community Health, Tufts University, Medford, USA.<br /><searchLink fieldCode="AU" term="%22Zhu+HB%22">Zhu HB</searchLink>; Information Management and Big Data Center, Nanfang Hospital, Southern Medical University, Guangzhou, China.<br /><searchLink fieldCode="AU" term="%22Guo+XJ%22">Guo XJ</searchLink>; Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.<br /><searchLink fieldCode="AU" term="%22Zhang+YP%22">Zhang YP</searchLink>; Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.; Information Management and Big Data Center, Nanfang Hospital, Southern Medical University, Guangzhou, China.<br /><searchLink fieldCode="AU" term="%22Guo+ZQ%22">Guo ZQ</searchLink>; Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.<br /><searchLink fieldCode="AU" term="%22Wu+DH%22">Wu DH</searchLink>; Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.<br /><searchLink fieldCode="AU" term="%22Dong+ZY%22">Dong ZY</searchLink>; Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101570526%22">Oncoimmunology</searchLink> [Oncoimmunology] 2021 Apr 26; Vol. 10 (1), pp. 1909296. <i>Date of Electronic Publication: </i>2021 Apr 26. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Taylor+%26+Francis%22">Taylor & Francis </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101570526 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2162-402X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2221624011%22">21624011 </searchLink><i>NLM ISO Abbreviation: </i>Oncoimmunology <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=33996262 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1080/2162402X.2021.1909296 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 1909296 Titles: – TitleFull: Integrative evaluation of primary and metastatic lesion spectrum to guide anti-PD-L1 therapy of non-small cell lung cancer: results from two randomized studies. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Ma SC – PersonEntity: Name: NameFull: Tang XR – PersonEntity: Name: NameFull: Long LL – PersonEntity: Name: NameFull: Bai X – PersonEntity: Name: NameFull: Zhou JG – PersonEntity: Name: NameFull: Duan ZJ – PersonEntity: Name: NameFull: Wang J – PersonEntity: Name: NameFull: Fu QJ – PersonEntity: Name: NameFull: Zhu HB – PersonEntity: Name: NameFull: Guo XJ – PersonEntity: Name: NameFull: Zhang YP – PersonEntity: Name: NameFull: Guo ZQ – PersonEntity: Name: NameFull: Wu DH – PersonEntity: Name: NameFull: Dong ZY IsPartOfRelationships: – BibEntity: Dates: – D: 26 M: 04 Text: 2021 Apr 26 Type: published Y: 2021 Identifiers: – Type: issn-electronic Value: 2162-402X Numbering: – Type: volume Value: 10 – Type: issue Value: 1 Titles: – TitleFull: Oncoimmunology Type: main |
| ResultId | 1 |
